الفهرس 
The effect of phosphodiesterase 5 inhibitor on pulmonary hypertension in patients with idiopathic pulmonary fibrosis
contentsOnly 14 pages are availabe for public view
 |  | from | 140 |  |  |
| | | from | 140 | | |
Abstract
Pulmonary hypertension (PH) is commonly observed in patients with advanced idiopathic pulmonary fibrosis (IPF). Despite the availability of therapies for both IPF and PH, none are approved for PH treatment in the context of interstitial pulmonary diseases. This study was conducted to assess the effect of phosphodiesterase 5 inhibitors (sildenafil) on pulmonary hypertension in patients with idiopathic pulmonary fibrosis after 3 months of treatment as regards as clinical & echocardiography findings. This study was conducted in Chest department, Kasr Al Ainy hospital, Cairo University; it included fifty patients with pulmonary hypertension secondary to idiopathic pulmonary fibrosis. The patients were divided into two groups: The first group included thirty patients that receivedphosphodiesterase 5 inhibitor; the second group included twenty patients that didn{u2019}t receive phosphodiesterase 5 inhibitor. Among the studied patients, there was statistically significant difference between the two groupsas regards as class of dyspnea, six minute walk distance, partial pressure of oxygen &Forced vital capacityfavoring the treatment group, but no statistically significant difference in the change of pulmonary artery systolic pressure measured by echocardiography between the two groups